Untargeted Lipidomics Analysis in Metabolic Dysfunction-Associated Steatohepatitis Associated with Morbid Obesity

Read the full article See related articles

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Background & Aims : Currently, there is a need to identify non-invasive biomarkers for an accurate diagnosis of Metabolic Dysfunction-Associated Steatohepatitis (MASH). Therefore, our aim was to perform untargeted lipidomics to identify the circulating lipid metabolite profile of MASH. Methods : We assessed a liquid chromatography coupled to a mass spectrometer-based untargeted lipidomic assay in serum samples of 216 women with morbid obesity that were stratified according to their hepatic histology into Normal Liver (n = 44), Simple Steatosis (SS, n = 66) and MASH (n = 106). Results : First, we identified a profile of lipid metabolites that are increased in Metabolic Dysfunction-Associated Steatotic Liver Disease, composed of ceramides, triacylglycerols and some phospholipids. Then, we identified that patients with SS have a characteristic profile of increased levels of ceramides, diacylglycerols DG (36:2) and DG (36:4), some triacylglycerols and a few phospholipids such as PC (32:1), PE (38:3), PE (40:6), PI (32:0) and PI (32:1). Later, in MASH patients, we found increased levels of ceramides, deoxycholic acid, a set of triacylglycerols, and some phospholipids such as PC, PE, PI and LPI, while we found decreased levels of the DG (36:0). Finally, we have reported a panel of lipid metabolites that are discriminatory and specific to patients with MASH compared to SS patients, made up of increased levels of 9-HODE some PC and PE, LPI (16:0) and decreased levels of DG (36:0). Conclusions : Our investigation has reported a lipid metabolite profile associated with MASH that could be used as a non-invasive diagnostic tool.

Article activity feed